The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios （OR） and corresponding 95% confidence intervals （CIs） were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models （GG vs. TT： OR, 1.123; 95% CI, 1.056--1.193; GG/GT vs. TT： OR, 1.028; 95% CI, 1.006--1.050）. In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital-/population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer （GG vs. TT： OR, 0.606; 95% CI, 0.407-0.903; GG/GT vs. TT： OR, 0.748; 95% CI, 0.579--0.968）. In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
It has been reported that the CCR5-Delta32,CCR2-64I and SDF1-3’A polymorphisms have protective effects against...
XU Li-dan~(1,*),QIAO Yuan-dong~1,ZHANG Xue-long~1,SUN Hai-ming~1,WANG Jing-wei~1,SUN Dong-lin~1,JIN Yan~1, YU Yang~1,CHEN Feng~1,BAI Jing~1,LING Hong~2,WANG Kai-li~3,FU Song-bin~(1,4).(1 Laboratory of Medical Genetics, Harbin Medical UniversityHarbin 1500812 Department of Microbiology,Harbin Medical UniversityHarbin 1500813 Heilongjiang Center for Disease Control and PreventionHarbin 1500304 Bio-pharmaceutical Key Laboratory of Heilongjiang Province,Harbin 150081,China)
